Patents by Inventor Mark R. Hellberg

Mark R. Hellberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NPR-B agonists
    Patent number: 9982016
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 29, 2018
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS
    Publication number: 20180094029
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Methods of treating ophthalmic diseases using NPR-B agonists
    Patent number: 9822147
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: November 21, 2017
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • NPR-B Agonists
    Publication number: 20170313743
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • NPR-B agonists
    Patent number: 9745344
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: August 29, 2017
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS
    Publication number: 20170101440
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: November 12, 2015
    Publication date: April 13, 2017
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Cyclic peptide-based NPR-B agonists
    Patent number: 9458198
    Abstract: Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: October 4, 2016
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Novel NPR-B Agonists
    Publication number: 20160194357
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: August 12, 2015
    Publication date: July 7, 2016
    Inventors: Frank Ostercamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • TOPICAL OCULAR ANALGESIC AGENTS
    Publication number: 20160089375
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.
    Type: Application
    Filed: October 9, 2015
    Publication date: March 31, 2016
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • Topical ocular analgesic agents
    Patent number: 9187468
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: November 17, 2015
    Assignee: NOVARTIS AG
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • Methods of treating ophthalmic diseases using NPR-B agonists
    Patent number: 9187525
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: November 17, 2015
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • NPR-B agonists
    Patent number: 9169293
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: October 27, 2015
    Assignee: Shire Orphan Thereapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME
    Publication number: 20140371267
    Abstract: The present invention is directed to the provision of ophthalmic compositions such as multi-dose, topical, ophthalmic compositions. The compositions include a nitric oxide (NO) donor compound.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Mark R. Hellberg, Peter G. Klimko, Jesse A. May, Suchismita Mohapatra
  • Method of Accelerating Corneal Wound Healing
    Publication number: 20140228430
    Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.
    Type: Application
    Filed: January 16, 2014
    Publication date: August 14, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni, Eric C. Carlson
  • TOPICAL OCULAR ANALGESIC AGENTS
    Publication number: 20140228338
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topcial ocular pharmaceutical composition are also disclosed.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 14, 2014
    Applicant: Novartis AG
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • NOVEL NPR-B AGONISTS
    Publication number: 20130345136
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • NOVEL NPR-B AGONISTS
    Publication number: 20130345394
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE
    Publication number: 20130274216
    Abstract: The present invention relates to ophthalmic compositions comprising inhibitors of spleen tyrosine kinase (syk). The compositions are particularly well suited for the treatment of ophthalmic infection such as fungal keratitis. The compositions optionally comprise an antiinfective compound such as an antibacterial or antifungal compound. The present invention also relates to methods for treating fungal keratitis using compositions comprising syk inhibitors.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 17, 2013
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Eric C. Carlson, Mark R. Hellberg, John M. Yanni
  • NPR-B agonists
    Patent number: 8551938
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 8, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • NPR-B agonists
    Patent number: 8546523
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 1, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg